EP
IONS icon

Eversept Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Eversept Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.7M Buy
664,684
+32,584
+5% +$2.45M 2.73% 10
2026
Q1 		$47.5M Buy
632,100
+93,882
+17% +$7.41M 2.5% 12
2025
Q4 		$42.6M Sell
538,218
-443
-0.1% -$33.4K 2.15% 13
2025
Q3 		$35.2M Sell
538,661
-50,239
-9% -$2.45M 2.43% 13
2025
Q2 		$23.3M Buy
588,900
+71,879
+14% +$2.35M 2.14% 11
2025
Q1 		$15.6M Buy
517,021
+302,069
+141% +$9.89M 1.58% 24
2024
Q4 		$7.51M Sell
214,952
-256,403
-54% -$9.58M 0.67% 31
2024
Q3 		$18.9M Buy
471,355
+14,474
+3% +$673K 1.29% 21
2024
Q2 		$21.8M Buy
456,881
+80,443
+21% +$3.3M 1.49% 17
2024
Q1 		$16.3M Buy
376,438
+51,784
+16% +$2.47M 1.09% 19
2023
Q4 		$16.4M Buy
324,654
+72,208
+29% +$3.46M 1.44% 18
2023
Q3 		$11.5M Buy
252,446
+10,874
+5% +$449K 0.97% 22
2023
Q2 		$9.91M Sell
241,572
-61,797
-20% -$2.37M 0.83% 27
2023
Q1 		$10.8M Buy
303,369
+62,394
+26% +$2.34M 0.76% 29
2022
Q4 		$9.1M Buy
240,975
+39,142
+19% +$1.65M 0.8% 27
2022
Q3 		$8.93M Buy
201,833
+115,522
+134% +$4.87M 0.77% 30
2022
Q2 		$3.2M Sell
86,311
-72,495
-46% -$2.73M 0.23% 54
2022
Q1 		$5.88M Sell
158,806
-225,983
-59% -$7.4M 0.45% 46
2021
Q4 		$11.7M Sell
384,789
-65,712
-15% -$2.07M 0.75% 38
2021
Q3 		$15.1M Buy
450,501
+8,501
+2% +$320K 1.05% 29
2021
Q2 		$17.6M Buy
+442,000
New +$17.3M 1.18% 26

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Eversept Partners's IONS Position: Q2 2026 in Review

Eversept Partners increased its Ionis Pharmaceuticals (IONS) stake by 5.2% in Q2 2026, buying an estimated $2.45M and bringing the position to 664,684 shares worth $52.7M. The position accounts for 2.73% of the portfolio, ranked #10.

Eversept Partners first reported a position in IONS in Q2 2021 and has held it in 21 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Eversept Partners held 664,684 shares of Ionis Pharmaceuticals worth $52.7M as of Q2 2026.
  • Eversept Partners bought 32,584 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.45M.
  • Ionis Pharmaceuticals made up 2.73% of Eversept Partners's portfolio in Q2 2026, its #10 holding.
  • Eversept Partners first reported a position in Ionis Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.